Novo Nordisk A/s

This study tests a once-weekly injection called CagriSema (a mix of cagrilintide and semaglutide) in 80 children and adolescents with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The trial lasts about 15 months, with everyone…

This Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to gr…

This early-stage study will compare two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version for several weeks, and researchers will measure how the drug builds up in the body. The goal is to s…

This study tests a new medicine called CagriSema to help people with type 2 diabetes lower their blood sugar. It compares two versions of the drug given by different injection devices. About 400 adults aged 18-64 with diabetes will take part for around 38 weeks. CagriSema is stil…

This study looks at how well a new insulin called icodec controls blood sugar in adults with type 2 diabetes who are switching from their current daily insulin. About 214 participants in Italy will use icodec as prescribed by their doctor for 22 to 30 weeks. Researchers will meas…

This study tests a new medicine called NNC0487-0111 in about 5,600 people who have both heart failure and obesity. Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug reduces the risk of heart failure worsening, hospitalization,…

This study tests a new medicine called CagriSema to help people with overweight or obesity lose weight. About 1,400 adults will receive either CagriSema or a placebo for around one year. The main goal is to see how much weight they lose and check for any side effects.

This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The stu…

This study looks at the safety and effectiveness of Rybelsus, a pill for type 2 diabetes, in everyday medical practice in Korea. About 600 adults will take the medicine as their doctor prescribes, and researchers will track side effects and blood sugar control for 26 weeks. The g…

This early-stage study tests two versions of the experimental medicine cagrilintide in 234 adults with overweight or obesity. Participants receive either version D or version B by chance, and researchers compare how the drug behaves in the body over about 6 months. The goal is to…

This study tests whether a new medicine called cagrilintide causes fewer stomach side effects than a placebo in people with obesity who had to stop taking other weight-loss drugs (GLP-1s) because of stomach issues. About 114 adults will be randomly assigned to receive either cagr…

This early-stage study tests whether a new drug called NNC0113-5840 is safe for people with overweight or obesity. About 48 adults aged 18-55 with a BMI between 25 and 35 will receive either the drug or a placebo. The main goal is to check for side effects and how the drug moves …

This study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and…

This early-stage study tests a new drug called CDR132L in 32 healthy adults. Researchers want to see how much of the drug gets into the blood when given as a shot under the skin compared to an IV drip. The goal is to find the best way to give this medicine to people with heart fa…

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…